Ionis Pharmaceuticals, Inc. (IONS)
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2025 Earnings Conference Call July 30, 2025 11:30 AM ET Company Participants Brett P. Monia - Founder, CEO & Director D.
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to a loss of $0.45 per share a year ago.
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?
After reaching an important support level, Ionis Pharmaceuticals, Inc. (IONS) could be a good stock pick from a technical perspective. IONS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ionis: After Years Of Investment, The Wholly-Owned Payoff Is In Sight
Ionis is transitioning from a licensing model to a commercial-stage biotech, investing heavily in its own drug launches and development pipeline. Upcoming catalysts include donidalorsen's FDA decision and olezarsen's Phase 3 data, both with significant peak sales potential in underserved markets. Despite ongoing losses and commercial execution risks, Ionis' validated platform and differentiated drugs offer compelling long-term growth opportunities.
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP & Chief Global Product Strategy Officer Beth Hougen - EVP, Finance & CFO Jonathan Birchall - SVP & Chief Commercial Officer Eugene Schneider - EVP, Chief Clinical Development & Operations Officer Conference Call Participants Jay Olson - Oppenheimer Gary Nachman - Raymond James Debjit Chattopadhyay - Guggenheim Jessica Fye - JPMorgan Chi Meng Fong - Bank of America Merrill Lynch Yaron Werber - TD Cowen David Lebowitz - Citi Mani Foroohar - Leerink Mike Ulz - Morgan Stanley Operator Good morning, and welcome to the Ionis First Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
